GlassScriptPhysician profile
Rohan Prasad
NPI 1356966337
$12,919.77
in general payments reported to CMS, 2019-2025
29 companies · $3,052 in 2025
The $3,052 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $199 · 2023: $4,345 · 2024: $5,018 · 2025: $3,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,650 · Food and Beverage: $4,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,650.00 |
| Food and Beverage | $4,765.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,824.53 | 2023-2025 | Assurity, Tacticath Ablation Catheter, Sensor Enabled, Tacticath |
| Amgen INC. | $658.99 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $641.20 | 2021-2025 | Brilinta, Farxiga |
| Boston Scientific Corporation | $584.15 | 2021-2025 | Watchman Flx, Watchman |
| Pfizer INC. | $540.53 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.67 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $210.52 | 2023-2024 | Camzyos, Eliquis |
| Abiomed | $201.30 | 2024-2025 | Impella |
| Medtronic, INC. | $190.54 | 2024-2025 | Corevalve Evolut R, Linq II, Micra |
| Philips North America LLC | $182.25 | 2023 | |
| Novartis Pharmaceuticals Corporation | $181.41 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $156.76 | 2024-2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $150.92 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $141.58 | 2024 | Xarelto |
| Lilly USA, LLC | $119.70 | 2025 | Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $115.92 | 2021-2024 | Pascal |
| Gilead Sciences, INC. | $113.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.04 | 2024-2025 | |
| Axsome Therapeutics, INC. | $100.80 | 2025 | Auvelity |
| Shockwave Medical, INC | $80.26 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $71.32 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $44.90 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $44.12 | 2025 | Attruby |
| United Therapeutics Corporation | $25.93 | 2025 | Tyvaso |
| Terumo Medical Corporation | $25.59 | 2025 | Tr Band, Angio-Seal |
| Abbvie INC. | $19.91 | 2022 | |
| Dynavax Technologies Corporation | $17.46 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.46 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.